Viromed Medical AG reports promising study results for PulmoPlas in intensive care unit ventilator-associated pneumonia patients

EQS-News: Viromed Medical AG / Key word(s): Study Viromed Medical AG reports promising study results for PulmoPlas in intensive care unit ventilator-associated pneumonia patients 14.03.2025 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Viromed Medical AG reports promising study results for PulmoPlas in intensive care unit ventilator-associated pneumonia patients

Pinneberg, Germany, March 14, 2025 - Viromed Medical AG (“Viromed”, Ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in room air sterilization, wound healing, and intensive care medicine, today announces promising study results for treating  ventilator-associated pneumonia (VAP) in intensive care unit (ICU) patients using its cold atmospheric pressure plasma device candidate, PulmoPlas. VAP is a severe lung infection caused by hospital-acquired germs in mechanically ventilated patients, with an estimated mortality rate of 10-13%.

The study led by Prof. Hortense Slevogt, Hannover Medical School, and Helmholtz Centre for Infection Research, shows that the treatment with PulmoPlas destroys bacteria in the upper and lower airways, including the hard-to-reach lower alveoli in 30 -90 seconds (in MRSA bacteria). The procedure is characterized by a high degree of tolerability, without any harmful effects on the respiratory epithelia (bronchial and alveolar).

"The results of our clinical trial have far exceeded our expectations in terms of efficacy and safety. Based on the available data, we are convinced that PulmoPlas therapy will revolutionize pneumonia treatment worldwide," said Uwe Perbandt, CEO of Viromed Medical AG. "Our innovative procedure has the potential to save lives and significantly shorten hospital stays, and thus could benefit all hospitals with ICUs. As the only company in the world that can offer such a treatment, we are aware of our responsibility and will work vigorously to make PulmoPlas available to hospitals as quickly as possible."